Physician profile
Dmitry Byk
NPI 1194826511
$69,928.59
in general payments reported to CMS, 2019-2025
28 companies · $685 in 2025
The $685 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $9,212 · 2021: $12K · 2022: $6,817 · 2023: $16K · 2024: $2,730 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $3,686 · Consulting Fee: $2,013 · Travel and Lodging: $1,419 · Education: $12.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,600.00 |
| Food and Beverage | $3,685.77 |
| Consulting Fee | $2,012.50 |
| Travel and Lodging | $1,418.77 |
| Education | $12.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29,878.02 | 2019-2020 | |
| Abbvie INC. | $29,174.37 | 2021-2023 | Vraylar |
| Bausch Health US, LLC | $2,419.26 | 2021-2024 | Aplenzin |
| Vanda Pharmaceuticals INC. | $1,330.88 | 2020-2024 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,330.27 | 2021-2025 | Caplyta |
| Lundbeck LLC | $1,027.90 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $725.17 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $720.97 | 2019-2023 | Austedo, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $607.14 | 2019-2023 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $583.43 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $563.50 | 2019-2023 | Spravato |
| Alkermes, INC. | $488.70 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $273.89 | 2020-2023 | Ingrezza |
| Tris Pharma INC | $269.92 | 2023-2025 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $112.47 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $77.51 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $65.79 | 2023-2024 | Quviviq |
| Orexo US, INC. | $43.64 | 2019 | |
| Shire North American Group INC | $39.58 | 2019 | |
| Almatica Pharma LLC | $38.93 | 2021-2022 | |
| Alfasigma USA, INC. | $32.78 | 2020-2021 | |
| Livanova USA, INC. | $21.43 | 2021 | |
| Corium, LLC | $19.86 | 2022 | |
| Eisai INC. | $18.67 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.54 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.69 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.33 | 2019 | |
| Merck Sharp & Dohme LLC | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Byk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.